Published in J Hepatol on December 15, 2010
Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1 | NCT00089570
Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology (2012) 2.01
Effect of various drugs used in conservative therapy of hepatorenal syndrome: a retrospective drug utilization study. Indian J Pharmacol (2014) 1.18
Kidneys in chronic liver diseases. World J Gastroenterol (2012) 1.10
Survival benefits of terlipressin and non-responder state in hepatorenal syndrome: a meta-analysis. Indian J Pharmacol (2013) 0.94
Recent advances in our understanding of hepatorenal syndrome. Nat Rev Gastroenterol Hepatol (2012) 0.94
Hepatorenal syndrome. World J Gastroenterol (2012) 0.93
Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). Wien Klin Wochenschr (2013) 0.93
Acute kidney injury in patients with cirrhosis: perils and promise. Clin Gastroenterol Hepatol (2013) 0.92
Urinary biomarkers and progression of AKI in patients with cirrhosis. Clin J Am Soc Nephrol (2014) 0.86
Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials. Am J Kidney Dis (2011) 0.85
Pharmacological management of hepatorenal syndrome: lessons from non-responders. J Hepatol (2011) 0.84
Randomized Controlled Trial Comparing the Efficacy of Terlipressin and Albumin with a Combination of Concurrent Dopamine, Furosemide, and Albumin in Hepatorenal Syndrome. J Clin Exp Hepatol (2015) 0.81
Renal dysfunction in patients with cirrhosis: Where do we stand? World J Gastrointest Pharmacol Ther (2014) 0.80
Renal dysfunction in cirrhosis is not just a vasomotor nephropathy. Kidney Int (2014) 0.79
Targeting an early and substantial increase in mean arterial pressure is critical in the management of type 1 hepatorenal syndrome: a combined retrospective and pilot study. Dig Dis Sci (2013) 0.78
Treatment and management of ascites and hepatorenal syndrome: an update. Therap Adv Gastroenterol (2015) 0.77
Dopamine and Furosemide for the Treatment of Hepatorenal Syndrome: A Reappraisal or Just Smoke and Mirrors? J Clin Exp Hepatol (2015) 0.76
Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis. BMC Gastroenterol (2015) 0.75
Hepatorenal syndrome:Response to terlipressin and albumin and its determinants. Pak J Med Sci (2016) 0.75
Acute kidney injury in the ICU: from injury to recovery: reports from the 5th Paris International Conference. Ann Intensive Care (2017) 0.75
Terlipressin and albumin for type 1 hepatorenal syndrome: does bacterial infection affect the response? Springerplus (2015) 0.75
Hepatorenal Acute Kidney Injury and the Importance of Raising Mean Arterial Pressure. Nephron (2015) 0.75
Hepatorenal syndrome: aetiology, diagnosis, and treatment. Gastroenterol Res Pract (2015) 0.75
Acute kidney injury in patients with chronic liver disease. World J Hepatol (2015) 0.75
The evolving concept of acute kidney injury in patients with cirrhosis. Nat Rev Gastroenterol Hepatol (2015) 0.75
Current position of vasoconstrictor and albumin infusion for type 1 hepatorenal syndrome. World J Gastrointest Pharmacol Ther (2015) 0.75
Hepatobiliary Quiz Answers-17 (2016). J Clin Exp Hepatol (2016) 0.75
Creatinine Change on Vasoconstrictors as Mortality Surrogate in Hepatorenal Syndrome: Systematic Review & Meta-Analysis. PLoS One (2015) 0.75
Hepatorenal syndrome: Update on diagnosis and therapy. World J Hepatol (2017) 0.75
Modulation of splanchnic circulation: Role in perioperative management of liver transplant patients. World J Gastroenterol (2016) 0.75
Hepatorenal syndrome: is it the magnitude of the renal failure that matters? Dig Dis Sci (2012) 0.75
[Management of severe alcoholic hepatitis]. Wien Med Wochenschr (2013) 0.75
Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology (2010) 8.11
Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology (1996) 4.54
Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut (2007) 4.51
Renal failure in cirrhosis. N Engl J Med (2009) 4.46
Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology (1988) 4.32
Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology (1993) 3.28
Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology (2007) 3.19
Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology (2008) 2.89
A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology (2008) 2.69
Acute kidney injury in cirrhosis. Hepatology (2008) 2.43
Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology (2010) 1.77
Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J Hepatol (2007) 1.44
An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol (2008) 1.27
Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol (2000) 1.24
Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology (2010) 1.21
Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis. J Gastroenterol Hepatol (2002) 1.20
Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology (2002) 1.20
Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci (2007) 1.18
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology (2007) 9.44
Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med (2005) 6.31
Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol (2005) 6.22
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology (2012) 5.47
Vascular disorders of the liver. Hepatology (2009) 5.38
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology (2003) 4.69
Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology (2007) 4.09
Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med (2008) 4.07
Acute-on chronic liver failure. J Hepatol (2012) 3.74
Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology (2008) 3.68
A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology (2007) 3.65
The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol (2013) 3.51
Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology (2002) 3.50
The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology (2009) 3.48
Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology (2004) 3.45
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Bacterial translocation (BT) in cirrhosis. Hepatology (2005) 3.07
Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology (2007) 3.06
Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology (2011) 2.97
The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology (2007) 2.94
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology (2005) 2.91
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology (2013) 2.82
Sepsis-induced cholestasis. Hepatology (2007) 2.80
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology (2013) 2.70
A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology (2008) 2.69
Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis (2008) 2.47
Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2009) 2.42
Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology (2009) 2.40
The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol (2011) 2.37
Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int (2010) 2.32
Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol (2009) 2.22
An explicit quality indicator set for measurement of quality of care in patients with cirrhosis. Clin Gastroenterol Hepatol (2010) 2.18
Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol (2003) 2.18
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials (2008) 2.17
Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy. Hepatology (2009) 2.16
Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int (2008) 2.10
Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology (2008) 2.10
Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology (2012) 2.01
Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr (2007) 1.99
Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab (2012) 1.97
Clostridium difficile is associated with poor outcomes in patients with cirrhosis: A national and tertiary center perspective. Am J Gastroenterol (2009) 1.93
The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. Hepatology (2013) 1.92
Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology (2007) 1.90
Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology (2014) 1.89
Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Am J Gastroenterol (2007) 1.87
Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. Hepatology (2012) 1.86
MELD-XI: a rational approach to "sickest first" liver transplantation in cirrhotic patients requiring anticoagulant therapy. Liver Transpl (2007) 1.86
Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol (2011) 1.85
Cirrhotic cardiomyopathy. J Am Coll Cardiol (2010) 1.77
Recommendations for probiotic use--2008. J Clin Gastroenterol (2008) 1.76
Effect of hyponatraemia on outcomes following orthotopic liver transplantation. Liver Int (2009) 1.76
Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transpl (2004) 1.76
Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol (2012) 1.70
Cardiac hemodynamic and coronary angiographic characteristics of patients being evaluated for liver transplantation. Am J Cardiol (2006) 1.64
Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology (2011) 1.63
The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol (2012) 1.61
Portal hypertensive bleeding. Gastroenterol Clin North Am (2003) 1.60
Serum B-type natriuretic peptide in the initial workup of patients with new onset ascites: a diagnostic accuracy study. Hepatology (2014) 1.60
Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. Liver Int (2009) 1.59
Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology (2010) 1.58
Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology (2010) 1.55
Intensive care of the patient with cirrhosis. Hepatology (2011) 1.54
Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. Gastroenterology (2010) 1.52
Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol (2010) 1.52
Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One (2013) 1.51
Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis. J Hepatol (2005) 1.51
Portal hypertension and its complications. Gastroenterology (2008) 1.50
Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology (2006) 1.50
Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp Clin Trials (2009) 1.48
Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl (2011) 1.44
Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis. Am J Gastroenterol (2004) 1.43
Recurrent variceal bleeding despite endoscopic and medical therapy. Gastroenterology (2004) 1.39
Treatment of portal hypertension. World J Gastroenterol (2012) 1.39
Ascites: diagnosis and management. Med Clin North Am (2009) 1.37
Drug-induced steatohepatitis. Clin Liver Dis (2003) 1.36
Renal dysfunction is the most important independent predictor of mortality in cirrhotic patients with spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol (2010) 1.36
New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology (2013) 1.35
A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol (2004) 1.33
Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. Liver Int (2012) 1.29
Endoplasmic reticulum stress and the unfolded protein response. Clin Liver Dis (2009) 1.28
Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology (2008) 1.24
Prevention of free fatty acid-induced hepatic lipotoxicity by 18beta-glycyrrhetinic acid through lysosomal and mitochondrial pathways. Hepatology (2008) 1.24
Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis (2004) 1.22
Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis. Hepatology (2008) 1.21
Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol (2009) 1.21
Patients' preferences for treatment of hepatitis C. Med Decis Making (2009) 1.20
Portal hypertension and variceal hemorrhage. Med Clin North Am (2008) 1.19
Association between metabolic syndrome and liver histology among children with nonalcoholic Fatty liver disease. Am J Gastroenterol (2010) 1.17